Main Article Content
Background: A high number of US citizens experience gastroesophageal reflux disease (GERD) symptoms at least once a month. These symptoms have a great impact on an individual’s quality of life and present a huge burden on healthcare systems. Diagnosis of GERD like symptoms is not straight forward and many individuals do not have a diagnosis with current tests being invasive, expensive and often with low patient compliance. To speed the diagnosis process up there are many individuals seeking self-diagnosis and it became apparent that an easily accessible, rapid, non-invasive and cost-effective diagnostic test would be well received by individuals.
Methods: Seven hundred and ninety-three self-referral individuals experiencing reflux like symptoms provided up to three saliva samples. The first on waking, the other two samples provided either post-prandial or post-symptom. All saliva samples were sent to a central laboratory for pepsin analysis using a lateral flow device containing two unique human monoclonal antibodies (Peptest). Following analysis, the pepsin concentration in each saliva sample was determined using a PepCube reader and expressed in ng/ml.
Results: A total of 1834 saliva samples were analysed for pepsin. Sixty-two percent of individuals tested had one or more saliva sample pepsin positive and 38% of individuals had all samples pepsin negative. The highest pepsin concentrations were seen in post-prandial samples with the lowest pepsin concentrations significantly lower (p=0.0127) in the on waking samples. The US interstate pepsin concentration data is limited due to low numbers of self-diagnosing individuals tested to date. There was no difference in pepsin concentrations between genders.
Conclusion: The individuals self-diagnosing their reflux like symptoms were mostly those aged 40 to 70 years. The availability of a simple easy to use non-invasive test for self-diagnosis is now widely accessible across all states of the US.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. de Bortoli, N., et al., Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they? Neurogastroenterol Motil, 2014. 26(1): p. 28-35. doi:10.1111/nmo.12221
3. NationalHeartburnAlliancesurvey. National Heartburn Alliance. Survey 2000 Results: A Community Perspective. 2000 April 17,2020; Available from: http://www.heartburnalliance.org/press-heartburn-survey.php.
4. Sharma, N., et al., An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol, 2008. 6(5): p. 521-4. doi:10.1016/j.cgh.2008.01.006
5. Vaezi, M.F., P.L. Schroeder, and J.E. Richter, Reproducibility of proximal probe pH parameters in 24-hour ambulatory esophageal pH monitoring. Am J Gastroenterol, 1997. 92(5): p. 825-9.
6. Du, X., et al., The diagnostic value of pepsin detection in saliva for gastro-esophageal reflux disease: a preliminary study from China. BMC Gastroenterology, 2017. 17(107): p. 1-9. doi:10.1186/s12876-017-0667-9
7. Wang, Y.F., et al., Validation in China of a non-invasive salivary pepsin biomarker containing two unique human pepsin monoclonal antibodies to diagnose gastroesophageal reflux disease. J Dig Dis, 2019. 20(6): p. 278-287. doi:10.1111/1751-2980.12783
8. Wang, Y.-J., et al., Salivary Pepsin as an Intrinsic Marker for Diagnosis of Sub-types of Gastroesophageal Reflux Disease and Gastroesophageal Reflux Disease-related Disorders. JNM, 2020. 26(1): p. 74-84. doi: 10.5056/jnm19032
9. Bardhan, K.D., V. Strugala, and P.W. Dettmar, Reflux Revisited: Advancing the Role of Pepsin. Int J Otolaryngol, 2012. 2012: p. 1-13. doi: 10.1155/2012/646901
10. Strugala, V., et al., Detection of pepsin in sputum: A rapid and objective measure of airways reflux. European Respiratory Journal, 2015. 47: p. 339-341. doi:10.1183/13993003.00827-2015
11. Strugala, V., et al., Use of pepsin detection to identify airways reflux in a range of pulmonary diseases. Clin Respir J, 2017. 11(5): p. 666-667. doi: 10.1111/crj.12395
12. Hayat, J.O., et al., Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease. Gut, 2015. 64(3): p. 373-380. doi: 10.1136/gutjnl-2014-307049
13. Crossfield, G., et al., Pepsin detection despite the use of acid suppressant medication in patients with airway reflux related chronic cough. Vol. 68 (Suppl 3). 2013; 68 (suppl 3): A19: Thorax. doi: 10.1136/thoraxjnl-2013-204457.38
14. Richter, J.E. and J.H. Rubenstein, Presentation and Epidemiology of Gastroesophageal Reflux Disease. Gastroenterology, 2018. 154(2): p. 267-276. doi: 10.1053/j.gastro.2017.07.045
15. Peery, A.F., et al., Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology, 2012. 143(5): p. 1179-1187. doi: 10.1053/j.gastro.2012.08.002
16. Boeckxstaens, G., et al., Symptomatic reflux disease: the present, the past and the future. Gut, 2014. 63(7): p. 1185-93. doi: 10.1136/gutjnl-2013-306393
17. Bytzer, P., et al., Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol, 2012. 10(12): p. 1360-6.
18. Kessing, B.F., et al., Effects of anxiety and depression in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol, 2015. 13(6): p. 1089-95. doi: 10.3748/wjg.v21.i14.4302
19. Van Oudenhove, L., et al., Relationship between anxiety and gastric sensorimotor function in functional dyspepsia. Psychosom Med, 2007. 69(5): p. 455-63. doi: 10.1097/PSY.0b013e3180600a4a
20. Jansson, C., et al., Severe gastro-oesophageal reflux symptoms in relation to anxiety, depression and coping in a population-based study. Aliment Pharmacol Ther, 2007. 26(5): p. 683-91. doi: 10.1111/j.1365-2036.2007.03411.x
21. Schwartz, M.P. and A.J. Smout, Review article: The endoscopic treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2007. 26 Suppl 2: p. 1-6. doi: 10.1111/j.1365-2036.2007.03473.x
22. Hershcovici, T. and R. Fass, An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol, 2010. 24(6): p. 923-36. doi: 10.1016/j.bpg.2010.10.004
23. Spechler, S.J., et al., Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA, 2001. 285(18): p. 2331-8. doi: 10.1001/jama.285.18.2331
24. Eusebi, L.H., et al., Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut, 2018. 67(3): p. 430-440. doi: 10.1136/gutjnl-2016-313589
25. Bor, S., et al., Validation of Peptest in Patients with Gastro-Esophageal Reflux Disease and Laryngopharyngeal Reflux Undergoing Impedance Testing. J Gastrointestin Liver Dis, 2019. 28(4): p. 383-387. doi: 10.15403/jgld-335
26. Dettmar, P., et al., A Multicentre Study in UK Voice Clinics Evaluating the Non-invasive Reflux Diagnostic Peptest in LPR Patients. SN Compr Clin Med, 2019. 2: p. 57-65. doi: 10.1007/s42399-019-00184-0
27. Dettmar, P.W., et al., Pepsin Detection as a Diagnostic Test for Reflux Disease, in Reflux Aspiration and Lung Disease. 2018, Springer International Publishing: United Kingdom. p. 91-104. doi: 10.1007/978-3-319-90525-9_8